NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.
A Verma, B Moghaddam
Journal of Neuroscience 1996 DOI: 10.1523/jneurosci.16-01-00373.1996 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Rats (Sprague-Dawley), male |
| Interventions | Ketamine Raclopride SCH-23390 Haloperidol |
| Dose | Ketamine 10-30 mg/kg; MK-801 0.1 and 0.5 mg/kg; raclopride 0.1 and 0.5 mg/kg; SCH-23390 0.1 mg/kg; haloperidol 0.1 mg/kg |
| Measures | Spatial delayed alternation performance, in vivo microdialysis of dopamine release |
| Topics | Ketamine |
| Keywords | Prefrontal cortex Neurons Animals Rats, sprague-dawley Dizocilpine maleate Receptors, n-methyl-d-aspartate Dopamine antagonists Maze learning Memory Time factors |
| Key findings | Ketamine and MK-801 dose-dependently impaired spatial delayed alternation, a prefrontal cortex-sensitive task, in rats. Haloperidol and raclopride, but not SCH-23390, reversed the impairment from 30 mg/kg ketamine, and microdialysis showed this ketamine dose preferentially raised prefrontal cortex dopamine release over the striatum. The authors conclude that NMDA receptor blockade impairs prefrontal cortex-dependent cognition, with dopamine activation contributing at least partly. |
Abstract
The present study was performed to assess the role of excitatory amino acid and dopamine receptors on associative functions of the prefrontal cortex (PFC) of the rat. Spatial delayed alternation was used as a PFC-sensitive cognitive task. In addition, in vivo microdialysis was used to assess the release of dopamine in the PFC. The noncompetitive NMDA antagonists ketamine (10-30 mg/kg) and MK-801 (0.1 and 0.5 mg/kg) dose-dependently impaired the spatial delayed alternation performance compared with the saline-treated control group. Administration of the dopamine antagonists raclopride (0.1 and 0.5 mg/kg), SCH-23390 (0.1 mg/kg), or haloperidol (0.1 mg/kg) was without a significant effect. However, haloperidol and raclopride (but not SCH-23390) reversed the disruptive effect of 30 mg/kg ketamine on spatial delayed alternation performance. Microdialysis studies revealed that this dose of ketamine preferentially increased the release of dopamine in the PFC compared with the striatum. These findings indicate that attenuation of glutamatergic neurotransmission at the NMDA receptor impairs PFC-dependent cognitive functions. Furthermore, activation of dopamine neurotransmission contributes, at least in part, to this impairment.
Citations in the library
Cited by 44
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders Molecular Psychiatry October 3, 2017
- A Review of the Nonmedical Use of Ketamine: Use, Users and Consequences Journal of Psychoactive Drugs December 1, 2000
- Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms. Biological Psychiatry January 8, 2021
- Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Research October 1, 2021
and 39 more in the library
Cites 4
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics March 1, 1992
- The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. Journal of Pharmacology and Experimental Therapeutics September 1, 1989